blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3215130

EP3215130 - PHARMACEUTICAL COMPOSITION COMPRISING BISOPROLOL AND PERINDORIL [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  20.01.2023
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  06.02.2020
FormerExamination is in progress
Status updated on  01.06.2018
FormerRequest for examination was made
Status updated on  11.08.2017
FormerThe international publication has been made
Status updated on  13.05.2017
Most recent event   Tooltip03.10.2024Change - lapse in a contracting state
State(s) deleted from list of lapses: AL		published on 06.11.2024  [2024/45]
Applicant(s)For all designated states
Les Laboratoires Servier
35, Rue de Verdun
92284 Suresnes / FR
[2017/37]
Inventor(s)01 / FONKNECHTEN, Gilles
Le petit chêne
Lieudit la Californie
45240 Ligny Le Ribault / FR
 [2017/37]
Representative(s)Casalonga
Casalonga & Partners
Bayerstraße 71/73
80335 München / DE
[N/P]
Application number, filing date15807949.104.11.2015
[2017/37]
WO2015FR52975
Priority number, dateFR2014006065405.11.2014         Original published format: FR 1460654
[2017/37]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2016071631
Date:12.05.2016
Language:FR
[2016/19]
Type: A1 Application with search report 
No.:EP3215130
Date:13.09.2017
Language:FR
The application published by WIPO in one of the EPO official languages on 12.05.2016 takes the place of the publication of the European patent application.
[2017/37]
Type: B1 Patent specification 
No.:EP3215130
Date:08.07.2020
Language:FR
[2020/28]
Search report(s)International search report - published on:EP12.05.2016
ClassificationIPC:A61K9/16, A61K9/24, A61K31/138, A61K31/404, A61K9/20, A61K9/48
[2020/07]
CPC:
A61K9/1652 (EP,EA,RU); A61K31/138 (EP,EA,RU); A61K31/404 (EP,EA,RU);
A61K9/0053 (RU); A61K9/2054 (EP,EA,RU); A61K9/209 (EP,EA,RU);
A61K9/4866 (EP,EA,RU); A61P9/00 (EP,RU); A61P9/12 (EP,RU) (-)
Former IPC [2017/37]A61K9/16, A61K9/24, A61K31/138, A61K31/404
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/37]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA04.05.2017
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT BISOPROLOL UND PERINDORIL[2017/37]
English:PHARMACEUTICAL COMPOSITION COMPRISING BISOPROLOL AND PERINDORIL[2017/37]
French:COMPOSITION PHARMACEUTIQUE COMPRENANT LE BISOPROLOL ET LE PÉRINDOPRIL[2017/37]
Entry into regional phase04.05.2017National basic fee paid 
04.05.2017Designation fee(s) paid 
04.05.2017Examination fee paid 
Examination procedure04.05.2017Examination requested  [2017/37]
04.05.2017Date on which the examining division has become responsible
05.06.2018Despatch of a communication from the examining division (Time limit: M04)
03.08.2018Reply to a communication from the examining division
07.02.2020Communication of intention to grant the patent
26.05.2020Fee for grant paid
26.05.2020Fee for publishing/printing paid
26.05.2020Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  08.04.2021  14.04.2021  ADMISSIBLE
KRKA, TOVARNA ZDRAVIL, d.d. Novo mesto
Smarjeska cesta 6
8000 Novo mesto / SI
Opponent's representative
Hoefer & Partner Patentanwälte mbB
Pilgersheimer Straße 20
81543 München / DE
 [2021/20]
21.04.2021Invitation to proprietor to file observations on the notice of opposition
31.08.2021Reply of patent proprietor to notice(s) of opposition
01.04.2022Cancellation of oral proceeding that was planned for 21.06.2022
21.06.2022Date of oral proceedings
22.07.2022Cancellation of oral proceeding that was planned for 11.10.2022
04.10.2022Despatch of communication that the patent will be revoked
11.10.2022Date of oral proceedings
14.10.2022Legal effect of revocation of patent [2023/08]
Fees paidRenewal fee
20.11.2017Renewal fee patent year 03
15.11.2018Renewal fee patent year 04
25.11.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipRS04.11.2015
SM08.07.2020
[2024/45]
Former [2024/34]RS04.11.2015
AL08.07.2020
SM08.07.2020
Former [2021/25]AL08.07.2020
SM08.07.2020
Former [2021/23]SM08.07.2020
Cited inInternational search[I] WO2007010501  (RANBAXY LAB LTD et al.) [I] 1-11 * page 2, line 8 - page 6, line 29 * * example - *
 [A] WO2010038091  (EGIS GYOGYSZERGYAR NYILVANOSAN et al.) [A] 1-11 * page 3 - page 6 *
OppositionWO2007010501
 WO2010038091
 US2004137054
 WO2011138772
   "LEHRBUCH DER PHARMAZEUTISCHEN TECHNOLOGIE,", 2002, article K. H. BAUER ET AL.: "chapter14", pages: 344 - 347, XP055797540
   E. TELEJKO: "Perindopril arginine: benefits of a new salt of the-ACE inhibitorperindopril", CURRENT MEDICAL RESEARCH AND OPINION, vol. 23, no. 5, 2007, pages 953 - 960, XP008152666

DOI:   http://dx.doi.org/10.1185/030079907X182158
   "Dosage Forms: Non-Parenterals", ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY, 2007, pages 988 - 993, XP055797579 * , 406-418 *
   P. REDDY ET AL.: "BI-LAYER TECHNOLOGY - AN EMERGING TREND: A REVIEW", INTERNATIONAL JOURNAL OF RESEARCH AND DEVELOPMENT IN PHARMACY AND LIFE SCIENCES, vol. 2, no. 3, May 2013 (2013-05-01), pages 404 - 411, XP055797575
   A. ABEBE ET AL.: "Review of bilayer tablet technology", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 461, 24 December 2013 (2013-12-24), pages 549 - 558, XP028810425, DOI: 10.1016/j.ijpharm.2013.12.028 * (D6, p. 549, "ARTICLE INFO") *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2013.12.028
   "Cardicor 2.5mg Film Coated Tablets", MEDICINES.ORG, 6 November 2020 (2020-11-06), XP055797566, Retrieved from the Internet
   A. MADEJ ET AL.: "Short-term antihypertensive therapy lowers the C-reactive protein level", POSTEPY HIG MED DOSW, vol. 66, 2012, pages 78 - 84, XP055797560
   KG ADAMYAN: "Bisoprolol and perindopril combination in post infarction left ventricle remodelling", CIRCULATION, vol. 118, no. 12, 2008, pages P373, XP055797555
   A. MADEJ ET AL.: "The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 47, no. 11, 2009, pages 686 - 694, XP055797549
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.